Timber Pharmaceuticals, Inc. (TMBR) News
Filter TMBR News Items
TMBR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TMBR News Highlights
- TMBR's 30 day story count now stands at 2.
- Over the past 24 days, the trend for TMBR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about TMBR are RARE, DRUG and EC.
Latest TMBR News From Around the Web
Below are the latest news stories about TIMBER PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TMBR as an investment opportunity.
Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology- Treatment with TMB-001 demonstrated greater proportions of participants achieving primary and key secondary endpoints versus vehicle regardless of the subtype of congenital ichthyosis - BASKING RIDGE, NJ, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today ann |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting off Friday morning with a breakdown of the biggest pre-market stock movers traders need to keep an eye on! |
Why Is Timber Pharmaceuticals (TMBR) Stock Up 61% Today?Timber Pharmaceuticals (TMBR) stock is taking off on Friday after getting an orphan drug designation for TMB-001 in Europe. |
Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive IchthyosisCompany Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ, Feb. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the European Commission (EC) granted orphan drug designation for TMB-001 |
Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward OutlookVirtual Business Briefing With Q&A to be Webcast on December 20, 2022 at 10:30 am ET BASKING RIDGE, NJ, Dec. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced it will host a virtual investor Business Briefing with Q&A on December 20, 2022, at 10:30 am ET. John Koconis, Ch |
Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing StandardsBASKING RIDGE, NJ, Dec. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the Company has received formal notice from The NYSE American LLC (“NYSE American”) stating that the Company has regained compliance with the NYSE American’s continued listing s |
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continues to progress; expected to enroll more than 140 patients with moderate to severe Congenital Ichthyosis- BASKING RIDGE, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments f |
Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock SplitBASKING RIDGE, NJ, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, announced today that it will effect a 1-for-50 reverse stock split of its outstanding common stock. Subject to NYSE American (“NYSE” or the “Exchange”) approval, the Company anticipates that trading |
Timber Pharmaceuticals Announces Halt of Common Stock TradingCompliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special Meeting of Stockholders on November 7, 2022 and Consummation of Reverse Stock Split BASKING RIDGE, NJ, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced th |
Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Timber Pharmaceuticals (TMBR)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB – Research Report) and Timber Pharmaceuticals (TMBR – Research Report) with bullish sentiments. Biogen (BIIB) In a report released today, Marc Goodman from SVB Securities maintained a Buy rating on Biogen, with a price target of $310.00. The company's shares closed last Tuesday at $273.56, close to its 52-week high of $284.59. According to TipRanks. |